Literature DB >> 3252042

Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers.

K A Thompson1, D H Iansmith, L A Siddoway, R L Woosley, D M Roden.   

Abstract

Marked interindividual variability has been reported in the plasma concentrations of the antiarrhythmic agent propafenone required for arrhythmia suppression. One possible explanation is the variable generation of active metabolites: it is known that the major metabolite 5-hydroxypropafenone and the more recently described metabolite N-depropylpropafenone can accumulate in plasma to concentrations similar to those of propafenone, and 5-hydroxypropafenone has proven active in animal models. We therefore compared the effects of these metabolites to those of propafenone on action potential characteristics of canine Purkinje fibers at a wide range of cycle lengths. After base-line measurements, propafenone or 5-hydroxypropafenone was superfused at successive concentrations of 0.1, 0.3 and 1.0 microM for 30 min each and measurements were repeated. Both drugs depressed maximum phase zero upstroke slope of the action potential (Vmax); 5-hydroxypropafenone was similar to propafenone in potency with both causing significant effects at very low concentrations (0.1 microM). Vmax depression was cycle length-dependent and the time constants for onset of and recovery from use-dependent Vmax depression were similar. The compounds also shortened action potential duration at 50% but not 90% repolarization. N-depropylpropafenone produced electrophysiologic effects that were similar to those of propafenone and 5-hydroxypropafenone but was less active. We conclude that these metabolites are sufficiently potent that they may explain at least in part the unpredictable concentration-response relationship seen with propafenone.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3252042

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.

Authors:  C Funck-Brentano; H K Kroemer; H Pavlou; R L Woosley; D M Roden
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 2.  Clinical significance of genetic influences on cardiovascular drug metabolism.

Authors:  L Arcavi; N L Benowitz
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

3.  Brugada syndrome, Brugada phenocopy or none?

Authors:  Umut Kocabas; Can Hasdemir; Esra Kaya; Cuneyt Turkoglu; Adrian Baranchuk
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-06-13       Impact factor: 1.468

4.  Short-term and long-term treatment with propafenone: determinants of arrhythmia suppression, persistence of efficacy, arrhythmogenesis, and side effects in patients with symptoms.

Authors:  M Zehender; S Hohnloser; A Geibel; A Furtwängler; M Olschewski; T Meinertz; H Just
Journal:  Br Heart J       Date:  1992-06

5.  Identification of propafenone metaboliser phenotype from plasma and urine excretion data.

Authors:  R Latini; M Belloni; R Bernasconi; E Cappiello; P Giani; M Landolina; D Leopaldi; J M Castel
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 6.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 7.  New antiarrhythmic drugs in pediatric use: propafenone.

Authors:  T Paul; J Janousek
Journal:  Pediatr Cardiol       Date:  1994 Jul-Aug       Impact factor: 1.655

Review 8.  Clinical pharmacokinetics of propafenone.

Authors:  J T Hii; H J Duff; E D Burgess
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

9.  Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites.

Authors:  M F Fromm; S Botsch; G Heinkele; J Evers; H K Kroemer
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 10.  Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal.

Authors:  A Capucci; G Boriani
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.